

For immediate release

ZOOMMED HAS FILED A PRELIMINARY PROSPECTUS AND AN APPLICATION FOR INCLUSION IN AN SME GROWTH STOCK PLAN.

Montreal, November 24, 2005 – **ZoomMed Inc.** (« **ZoomMed** »), TSX Venture: ZMD. M. Yves Marmet, President and Chief Executive Officer, announces that the corporation has filed a preliminary prospectus on November 8, 2005 with "les Autorités des Marchés Financiers" in Quebec and Ontario, for a minimum gross proceed of \$750,000 and a maximum gross proceed of \$2,500,000.

Furthermore, **ZoomMed** has obtained, on November 22, 2005, an advance income tax ruling from the "Ministère du Revenu du Québec" in order to confirm that the Common Shares of **ZoomMed** to be issued pursuant to this Offering will be eligible shares, upon issuance, for inclusion in an SME Growth Stock Plan in accordance with the announcements contained in the Additional Information on the Budgetary Measures of the 2005-2006 Budget tabled on April 21, 2005 and the current provisions of the Taxation Act (Québec), subject to certain conditions contained thereunder.

ZoomMed is presently developing a new electronic tool "ZRx Prescriber", intended to change the way drugs are prescribed and dispensed throughout Canada. This handheld prescribing system device, equipped with tools such as a therapeutic advisor as well as a medication interaction manager, will enable doctors to fill prescriptions and to electronically transmit them in a fast and secure mode. This user friendly Web product, designed for doctors, will use the latest "Pocket PC" technologies.

The net proceeds of this offering will be used to market and deploy the ZRx Prescriber, to market existing products, as well as for general and administrative fees and to provide working capital.

ZoomMed Inc. files its financial statements, press releases and other required filing documents on the SEDAR data base at www.sedar.com.

The preliminary prospectus is subject to approval by "les Autorités des Marchés financiers".

The TSX Venture Exchange has neither approved nor accepts any responsibility with respect to the veracity or exactitude of this press release.

Information: **Yves Marmet**, President and Chief Executive Officer **ZoomMed inc.** (450) 678-5457